Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi, miRNA and Epigenetics

Dong-Ki Lee's Biography

Dong-Ki Lee, CEO, Olix Pharmaceuticals

Prof. Dong-ki Lee received B. S. in Chemistry from Korea Advanced Institute of Science and Technology (KAIST) in 1993, and Ph. D. in Biochemistry from Cornell University in 1999. After post-doctoral training in Pohang University of Science and Technology (POSTECH), Toolgen Inc., and KAIST, he joined POSTECH as an assistant professor in 2004. In 2008, He moved to Sungkyunkwan University as an associate professor. In 2008, Prof. Lee was selected as the principal investigator of the Global Research Laboratory program to develop novel RNAi medicine. He is currently serving as the Asian editor of “Nucleic Acid Therapeutics” (formerly “Oligonucleotides”) and editorial board of "Molecular Therapy: Nucleic Acids". His work on novel siRNA structures, nucleic acid aptamers, and eukaryotic gene regulation has been published as over 50 papers including prestigious journals such as Nature, PNAS, and Molecular Therapy.

Dong-Ki Lee Image

Second Generation RNAi Triggers and their Therapeutic Applications

Wednesday, 14 November 2012 at 14:15

Add to Calendar ▼2012-11-14 14:15:002012-11-14 15:15:00Europe/LondonSecond Generation RNAi Triggers and their Therapeutic

In this presentation, several novel gene silencing siRNA structural variants developed in Prof. Lee’s laboratory will be introduced and discussed in light of the structural flexibility of RNAi machinery and therapeutic potentials.

Add to Calendar ▼2012-11-13 00:00:002012-11-14 00:00:00Europe/LondonRNAi, miRNA and